Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSelpercatinib, is a potent and selective receptor tyrosine kinase RET inhibitor (EC50 = 4 nM). It shows > 100-fold selectivity for > 95% of 228 purified kinase domains in radiometric assays. In vitro, it inhibits proliferation of cancer cell lines containing RET mutations or gene fusions. In vivo, it inhibits tumor growth in diverse RET mouse models. Selpercatinib is orally bioavailable.
Selpercatinib is also offered as part of the Tocriscreen Kinase Inhibitor Library. Find out more about compound libraries available from Tocris.
M. Wt | 525.6 |
Formula | C29H31N7O3 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 2152628-33-4 |
PubChem ID | 134436906 |
InChI Key | XIIOFHFUYBLOLW-UHFFFAOYSA-N |
Smiles | N#CC=1C=NN2C=C(OCC(O)(C)C)C=C(C=3C=NC(=CC3)N4CC5N(CC6=CN=C(OC)C=C6)C(C4)C5)C12 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 10.51 | 20 |
The following data is based on the product molecular weight 525.6. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.2 mM | 9.51 mL | 47.56 mL | 95.13 mL |
1 mM | 1.9 mL | 9.51 mL | 19.03 mL |
2 mM | 0.95 mL | 4.76 mL | 9.51 mL |
10 mM | 0.19 mL | 0.95 mL | 1.9 mL |
References are publications that support the biological activity of the product.
Subbiah et al (2018) Selective RET kinase inhibition for patients with RET-altered cancers. Ann.Oncol. 29 1869 PMID: 29912274
Brandhuber et al (2016) The development of LOXO-292, a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. International Conference on Molecular Targets and Cancer Therapeutics
If you know of a relevant reference for Selpercatinib, please let us know.
Keywords: Selpercatinib, Selpercatinib supplier, RET, tyrosine, kinases, selective, potent, inhibitors, inhibits, orally, bioavailable, Other, RTKs, 7696, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Selpercatinib. Do you know of a great paper that uses Selpercatinib from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Selpercatinib and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image